Exploring novel genomic biomarkers for response and survival after neoadjuvant chemotherapy and radical cystectomy of muscle-invasive bladder cancer.

ABSTRACT:

Background

Neoadjuvant cisplatin-based combination chemotherapy (NAC) is standard perioperative treatment of patients with muscle-invasive urothelial bladder cancer (MIBC); however, about half of the patients experience recurrence of the disease. Biomarkers for response and survival represent an unmet medical need. We used tumor specimens from transurethral resections of the bladder to explore genomic alterations and their association with response and survival in MIBC patients treated by NAC and radical cystectomy.

Patients and methods

A pan cancer panel with single-nucleotide polymorphism backbone-based sequencing approach with coverage of the most commonly perturbed cancer genes and low-pass whole genome sequencing was applied for genomic characterization of 110 clinical

SUBMITTER: Holmsten K 

PROVIDER: S-EPMC12281969 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature